Scientists develop largest ever biological AI model that ‘thinks in nucleotides’
A team of US scientists has developed a new foundation model that can sift through genetic code across biology's five …
Post
-
-
Supernus’s stock sinks after depression drug fails trial
Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an investigational treatment for adults …
-
Sanofi moves closer to selling controlling stake in $17bn-valued Opella
Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share …
-
Cumberland’s Vibativ injection gains China’s NMPA approval
Cumberland Pharmaceuticals' antibiotic Vibativ (telavancin) injection has gained approval from China’s National Medical Products Administration (NMPA), offering a new treatment …
-
Amazon joins forces with Memorial Sloan Kettering for AI-powered drug discovery
Amazon Web Services (AWS) and US-based Memorial Sloan Kettering Cancer Center (MSK) have announced a partnership to leverage artificial intelligence …
-
GLP-1RAs and opioid use disorder: a new frontier in addiction treatment
Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s tirzepatide (Mounjaro, Zepbound) have dominated headlines …
-
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all …
-
Can innovation in clinical trial delivery meet the demands of increasing complexity in drug development?
The pharmaceutical industry is facing growing complexity in clinical trials, contributing to longer timelines and ultimately higher costs. These complexities …
-
New CEOs to join Merck KGaA’s executive board
E Merck KG's board of partners has announced the appointment of new CEOs to Merck KGaA’s executive board in a …
-
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
Gilead is edging closer to an approval for its twice-yearly injectable human immunodeficiency virus-1 (HIV-1) capsid inhibitor, lenacapavir, as a …
-
Valneva hits 2024 sales target but plans lower cash burn in 2025
Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine …
-
EC conditionally approves MSD’s Welireg for VHL disease and RCC
The European Commission (EC) has conditionally approved MSD's Welireg, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, as a single agent …
-
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune …
-
HMRI and Novartis Australia sign MoU to expedite medical research
The Hunter Medical Research Institute (HMRI) has signed a memorandum of understanding (MoU) with Novartis Australia for expediting medical research …
-
FDA grants fast track status to Rznomics’ RZ-001 for HCC
The US Food and Drug Administration (FDA) has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular …
